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Abstract
This study uses the micro-simulation method to investigate the role of cohort forces in age-
dependent mortality pattern. We test the micro mechanisms for cohort evolution and mortality 
selection, and how these two biological and demographic forces may interact with epidemiologic 
transition to shape the cohort age-dependence of mortality pattern in both early- and later-
transition countries. We show that cohort evolution is due to the declining rate of mortality 
acceleration at the individual level, which is associated with lower initial mortality rates but not 
smaller variance offrailty distribution in later birth cohorts. The steeper slope of mortality 
acceleration at the population level among later birth cohorts is due to mortality selection 
mechanism associated with smaller variance of frailty distribution but not lower initial mortality 
rates. These two forces jointly shape the non-crossover cohort age-dependence of mortality pattern 
regardless of the differential mechanisms of epidemiologic transition in early- and later-transition 
countries.
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The forces shaping the cohort age-dependent mortality pattern is one of fundamental 
questions in formal demography. The technophysio evolution theory (Fogel and Costa 1997) 
and the cohort morbidity phenotype theory (Finch and Crimmins 2004) propose that due to 
the long-lasting protective consequences of a better health endowment and lower exposure to 
infection and inflammation in early life, subsequent birth cohorts experience lower age-
specific mortality rates throughout the life course. These theories are collectively referred to 
as the cohort evolution theories because they explain a positive correlation between young-
age mortality level and old-age mortality level across cohorts (Zheng 2014).
Meanwhile, the mortality selection mechanism, a process through which the fitter survive 
while the frailer die over a cohort’s life course, may cause later cohorts which have a smaller 
Address all correspondence to Hui Zheng, Department of Sociology, The Ohio State University, 106 Townsend Hall, 1885 Neil 
Avenue Mall, Columbus, OH 43210, zheng.64@osu.edu. 
HHS Public Access
Author manuscript
Biodemography Soc Biol. Author manuscript; available in PMC 2019 December 23.
Published in final edited form as:
Biodemography Soc Biol. 2018 ; 64(3-4): 216–236. doi:10.1080/19485565.2019.1568673.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
proportion of frail individuals in early life to have a more pronounced acceleration of 
mortality in late life than earlier cohorts, in which a larger proportion were frail. In other 
words, mortality selection mechanism suggests a negative correlation between young-age 
mortality level and the rate of mortality acceleration across birth cohorts. Therefore, cohort 
differences in life-course mortality pattern are determined by two mechanisms: cohort 
evolution and mortality selection. Zheng (2014) finds that among developed countries the 
mortality selection mechanism is not strong enough to override the cohort evolution 
mechanism; therefore old-age mortality rates are still lower among later cohorts than among 
earlier cohorts.
But several important questions remain. First, what is the micro mechanism for cohort 
evolution? Cohort evolution theories aggregate the positive correlation between early-life 
health and old-age health at the individual level to cohort (group) level. Yet to the contrary, 
the mortality selection mechanism implies that the cohort pattern may deviate from 
individual pattern. Understanding how these two competing forces shape mortality patterns 
requires not only a close examination of the micro processes over a cohort’s life cycle but 
also an cross cohort comparison that takes advantage of varying conditions for different 
cohorts of the population. Second, what is the micro mechanism for mortality selection? 
Several elements of the cohort life course process may determine the mechanism of 
mortality selection. Is the steeper slope of mortality acceleration at later cohort due to the 
observed lower mortality rate (Strehler and Mildvan 1960) or typically unobserved variance 
of frailty distribution (Yashin et al. 2002; Vaupel 2010)?
Third, is the non-crossover cohort mortality pattern jointly shaped by cohort evolution and 
mortality selection in countries that have experienced the epidemiologic transition in more 
recent periods? The main difference between early-and later-transition countries is the 
mechanism contributing to the mortality decline during receding pandemics. May the 
different historical mechanisms imply different processes of cohort evolution and mortality 
selection were at work in these countries? How epidemiologic transition, cohort evolution 
and mortality selection mechanisms interact and shape the cohort age-dependence of 
mortality pattern and affect historical mortality declines is still an unsolved question in 
demography.
Motivated by these questions, this study uses microsimulation to examine the role of cohort 
forces (cohort evolution and mortality selection) in age-dependent mortality pattern. More 
specifically, we aim to investigate the micro mechanisms for these two biological and 
demographic forces, and examine how they may interact with epidemiologic transition to 
shape the cohort age-dependence of mortality pattern in both early-and later-transition 
countries.
Cohort Evolution and Mortality Selection
Cohort morbidity phenotype theory proposes that when cohorts experience lower exposure 
to infection and inflammation during early childhood, they reap a lower mortality risk later 
in life (Finch and Crimmins 2004). Another theory, describing a trend of “technophysio 
evolution,” argues that later cohorts are endowed with better health capital at birth and enjoy 
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lower rates of health capital depreciation over the life course due to increasing control over 
the environment, improved food and energy production, other technological innovation, and 
economic growth (Fogel and Costa 1997; Fogel 2004a). Both theories suggest a positive 
correlation between early-and later-life mortality. Zheng (2014) further proposes that due to 
lower young-age mortality rates, the rate of biological aging at the individual level 
decelerates among later birth cohorts and contributes to the positive correlation between 
young-and old-age mortality rates across cohorts. These studies inspired our conjecture 
about cohort evolution:
Conjecture 1: According to cohort evolution theories, cohorts with lower young age 
mortality rates have lower rate of mortality acceleration at the individual level, 
which leads to lower mortality rates over the life course at the cohort level.
While cohort evolution theories attribute the positive correlation between young-and old-age 
mortality rates across birth cohorts to the positive correlation between early-life health and 
old-age health at the individual level (e.g., Bengtsson and Lindstrom 2003; Baker et al. 
1991), the mortality selection mechanism may imply the opposite pattern on the cohort 
level. The theory of population heterogeneity proposes that cohort is composed of 
individuals with different physiological vulnerability to mortality, or frailty (Vaupel et al. 
1979; Vaupel and Yashin 1987). Mortality tends to remove frailer individuals from the 
population at earlier ages, and leave stronger individuals to survive to older ages. Therefore, 
the mortality selection mechanism implies that the frailty composition within a given birth 
cohort changes over the life course, which may lead to a discrepancy in the individual-level 
and cohort-level mortality patterns.
For example, cohort evolution theories suggest that later cohorts experience lower risk of 
infection and inflammation and have better nutrition and health capital during childhood. 
Therefore, the variance of frailty in later cohorts is reduced, resulting in a smaller proportion 
of frail individuals being selected out of the population at young ages and a larger proportion 
of frail individuals to survive into old age. As a result, later cohorts may exhibit higher 
cohort-level mortality rate at older ages, not because mortality increases for individuals, but 
only because of the changed composition of the population that survive into older ages. In 
this case, the old-age mortality rate may be potentially higher among later cohorts than 
among earlier cohorts, even though the individual-level mortality risk is lower in later 
cohorts at all ages.
A useful illustration of this argument takes advantage of Gompertz’s (1825) classical law of 
mortality, which models the increase in mortality rates over adulthood within each birth 
cohort in an exponential pattern: ū (x) = aeβxas illustrated in Figure 1, where ū (x) is the 
cohort mortality rate at age x, a is the initial mortality rate, ln(α) is the intercept of log 
cohort mortality curve ln(ū (x)) = ln(α) + βx, and β refers to the rate of increase in the 
cohort mortality rate, alternately described as the rate of mortality acceleration (or the slope 
of log mortality curve). Whether later cohorts have lower old-age mortality rates than earlier 
cohorts is determined not only by the later cohorts’ lower young-age mortality rates as 
captured by ln(α) (i.e., the cohort evolution mechanism), but also by a higher rate of 
mortality acceleration in later cohorts as captured by β (i.e., the mortality selection 
mechanism).
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The theory of population heterogeneity emphasizes that the magnitude of β can depend on 
the variance of the distribution of frailty in the population within each birth cohort. “The 
slope of the mortality rate increases when the variance of heterogeneity distribution 
declines,” (Yashin et al. 2002:209; Vaupel 2010) because when a smaller proportion of frail 
individuals is selected out of the population at an early age, a larger proportion of frail 
individuals survives to older ages and the mortality curve at later ages becomes steeper:
Conjecture 2: According to the theory of population heterogeneity, cohorts with a 
smaller variance offrailty at young age should have a steeper slope of mortality 
acceleration.
While the population heterogeneity theory emphasizes the cross-cohort changes in the 
variance of frailty, Strehler and Mildvan’s (1960) general theory of mortality and aging 
proposes a different rule governing the slope of mortality acceleration. This theory posits 
that the initial mortality rate ln(α) and the slope β of the logarithm of the Gompertz 
mortality curve are negatively correlated. It remains unclear whether the level of initial 
mortality rate or the heterogeneity in frailty matters more for the cohort differences in the 
slope of mortality curve. We address this question by using microsimulation to examine the 
impact of the lowered young-age mortality on the slope of mortality and compare the result 
with that from Conjecture 2:
Conjecture 3: According to the Strehler and Mildvan’s general theory of mortality 
and aging, cohorts with lower young-age mortality rates should have a steeper slope 
of cohort mortality curve.
The Role of Cohort Evolution and Mortality Selection in Early-Transition 
Countries
Among early-transition countries, the initial young-age mortality reduction during the age of 
receding pandemics is mainly due to socioeconomic development and consequential 
improvements in hygiene and nutrition, which are a byproduct of social change rather than a 
result of advancements in medical technology (Omran 1971). Socioeconomic development 
both improves the health endowment and reduces exposure to inflammation among 
individuals born during this period. This specific mechanism of epidemiologic transition 
provides the conditions for the cohort evolution mechanism to take effect. Furthermore, 
socioeconomic development reduces the variance of the frailty distribution at young ages 
among later cohorts and amplifies mortality acceleration over the life course. Therefore, 
diminished mortality selection in early life among individuals born during the age of 
receding pandemics is also a result of socioeconomic development, and this socioeconomic 
development decreases the variance of the frailty distribution at young ages across cohorts 
gradually rather than abruptly. Thus, as Zheng (2014) suggested, the slope of the mortality 
curve will not be steep enough for older-age mortality rates among later cohorts to surpass 
those among earlier cohorts. This pattern is represented by the Sweden and Japan Panels of 
Figure 2.
These arguments lead to a fourth conjecture:
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Conjecture 4: Due to cohort evolution, among early-transition countries later 
cohorts with lower young age mortality rates should have lower mortality rates 
throughout the life course than preceding cohorts despite the function of mortality 
selection.
The Role of Cohort Evolution and Mortality Selection in Later-Transition 
Countries
In contrast, among later-transition countries the initial mortality reduction at young ages is 
mainly due to medical advancements rather than socioeconomic development, meaning that 
cohorts born in these countries during the age of receding pandemics might not have had 
significantly better nutrition or health endowment, or significantly lower exposure to 
inflammation, compared to earlier cohorts. Therefore, there might be no or weak effect of 
the cohort evolution mechanism. On the other hand, the mortality selection mechanism 
might have become a dominant determinant of cohort trends in the age-dependence of 
mortality rates. Vaccination, diffusion of drugs and medical technologies allow an increasing 
share of frail individuals to survive into adulthood who were nonetheless exposed to 
infection and inflammation in early life, the negative effect of which will affect them over 
the life course and may potentially increase mortality rates at old ages compared to earlier 
birth cohorts. Palloni and Souza (2013) posited that weakened mortality selection in the 
stage of receding pandemics in Latin American and the Caribbean countries may cause life 
expectancy at older ages to stall or even decline in the future.
A more complicated pattern has been observed in some Eastern European countries such as 
Bulgaria, where older-age mortality rates exhibit substantial two-step crossover across 
cohorts born at the age of receding pandemics (1930–1960) (see Figure 2). The 1940 birth 
cohort intersects with the 1930 birth cohort at ages 40 and 60. The intersection points 
between the 1940 and 1950 birth cohorts appear earlier in the life-course: at ages 30 and 50, 
respectively. The intersection points between the 1950 and 1960 birth cohorts appear even 
earlier in the life-course. Past the 1970 birth cohort, and especially past the 1980 birth 
cohort, mortality curves no longer cross over those of earlier cohorts. Bulgaria entered the 
age of receding pandemics in the 1930s, even later than Japan did, and went through this 
stage of transition at an even faster rate due to medical advancements. Its economies were 
largely rural; technology, capital and access to markets were lacking; and the Great 
Depression devastated every economic sector (Kaser and Radice 1987). Against this 
background of economic stagnation, medical treatment emerged as the main cause of initial 
declines in young-age mortality from the 1930s through the 1960s, and included the 
diffusion of vaccinations, drugs, and medical technology. Further mortality declines after the 
1970s, when Bulgaria started transitioning to the age of degenerative and man-made diseases 
(Vallin and Mesle 2004), became increasingly attributable to socioeconomic development, 
improved living standards, and improved nutrition.
But a different pattern is found in another later-transition country, Taiwan (Figure 2). There 
is no crossover in any birth cohorts from 1891 to 1980, which resembles the pattern in 
Sweden and Japan. Palloni and Souza (2013) presumed mortality crossover in old ages 
Zheng and Cheng Page 5
Biodemography Soc Biol. Author manuscript; available in PMC 2019 December 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
across cohorts in Latin American countries, but based on our reconstruction of period 
mortality data to cohort age-specific mortality rates in Mexico and Chile, no mortality 
crossover has been found either. These counterexamples question the cohort frailty 
arguments about mortality crossover at old age in later transition countries. The competing 
argument is there may be some spill-over effects from reduction in the intensity and duration 
of illnesses induced by medical technology. There is a synergistic relationship between 
nutrition and infection (Scrimshaw and SanGiovanni 1997). Improved nutrition can increase 
resistance to infection and improve recovery from illness (Scrimshaw 1992, 1997; Fogel 
2004b), while lower contraction rate of infectious diseases (due to vaccination) and reduced 
duration and severity of infection and better recovery from diseases (due to medical 
treatment) can be translated to better nutrition status even in the absence of improvement in 
nutrition intake (Palloni and Souza 2013). Thus, even though living standards and nutrition 
intakes might not significantly improve at the stage of receding pandemics in the later-
transition countries, people born during that time might be relatively better off than 
preceding cohorts due to a significant reduction in nutrition loss caused by medical 
technologies. In this case, cohort evolution mechanism may still function in that stage. 
Following this argument, the age-specific mortality curve should not have crossed over 
across birth cohorts if only cohort mechanisms are working. In other words, the two-step 
cross-over in some Eastern European countries should have been caused by period shocks.
These arguments lead to a fifth and sixth conjecture:
Conjecture 5: Medical improvement-induced receding pandemics among later-
transition countries saved an increasing share of frail individuals who had been 
exposed to adverse early conditions and allowed them to survive to adulthood, 
which led to significantly larger share of frail individuals at older ages and caused 
the mortality crossover across birth cohorts.
Conjecture 6: Medical improvement-induced receding pandemics among later-
transition countries reduced exposure, duration and severity of infection and 
improved recovery from diseases, which translated to better nutrition status and 
enabled cohort evolution mechanism. Therefore, the mortality curve should not 
cross over across birth cohorts. The observed or expected crossover was driven by 
period trends.
Research Design and Model Setup
In order to test the above six conjectures, we use the microsimulation method to simulate the 
observed cohort age-dependent mortality pattern from age 30 to 90 on the individual hazard 
curve only allowing the cohort mechanisms to function in early-transition countries 
represented by Sweden and later-transition countries represented by Bulgaria. We start with 
age 30 because cohort mortality curve follows a Gompertz law beginning at that age. We 
restrict the upper end to age 90 due to uncertainty of hazard function at very old ages 
(Crimmins and Finch 2006). We only present simulations on male mortality pattern for the 
sake of space. Empirical mortality data on these countries are available from the Human 
Mortality Database (http://www.mortality.org/).
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Basic mathematical formulation
Following Vaupel et al. (1979), suppose that individuals in a cohort differ from each other in 
the value of frailty (denoted as z) characterizing their susceptibility to death, such that their 
force of mortality conditional on z is
ui x = ziu0 x (1)
where ui (x) is the force of mortality for individual i at instantaneous age x, zi is frailty for 
individual i at initial age, u0 (x) is the unobserved baseline hazard function with frailty of 1. 
An individual with a frailty of 1 can be called a “standard” individual. An individual with 
frailty of 1.5 is one and half times more likely to die at any particular age than the standard 
individual. Frailty zi follows a gamma distribution at initial age, with p.d.f.: where λ and k 
are the parameters of the distribution. The mean and variance of a gamma variate are given 
by:
f 0(z) = λ
kZk − 1e−λz/Γ(k) (2)
where λ and k are the parameters of the distribution. The mean and variance of a gamma 
variate are given by:
z = k /λ (3a)
σ2 = k /λ2 (3b)
We follow earlier work to set mean frailty z as 1 (which is also the value of frailty for a 
“standard” individual). Thus the shape parameter k equals λ, and the variance of frailty 
distribution σ2 equals the inverse of k.
The mortality selection mechanism yields a cohort-level force of mortality ū (x) as
u(x) =
u0(x)
1 + σ2H(x)
, (4)
where the cumulative hazard function from initial age to age x is H(x) = H(x) = ∫ 0xu0(t)dt
(Vauple et al. 1979). From formula (4), it is obvious that cohort mortality function ū(x) 
deviates from individual hazard function u0(x). The higher value of the variance of frailty 
distribution σ2, the more the slope of ū(x) deviates from that of u0 (x); the deviation also 
increases with age as H(x) is an increasing function of x (Yashin et al. 2002).
Even though cohort mortality function ū (x) in discrete time is observed and is often 
parameterized as a Gompertz function, there are limited empirical data to support any 
conjecture about individual hazard curve. The theory of population heterogeneity posits that 
death selectively removes the frailest members of a cohort so that mortality rate at cohort 
level becomes increasingly dominated by robust members over the life course (Vaupel et al. 
1979; Vaupel and Yashin 1985). This means that individual hazard curve should be steeper 
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than cohort mortality curve, or individuals “age” faster than heterogeneous cohorts (Vaupel 
and Yashin 1983). This conclusion is also inferred from formula (4). Yashin and Iachine 
(1997) infer the underlying individual hazard function from the semiparametric shared-
frailty model using Danish twins data, and findings support the assumption that individuals 
age faster than cohorts.
Following Vaupel and Yashin (1983) with some modification, we assume individual baseline 
hazard function as
u0(x) = ae
bxe
a ebx − 1
b .
(5)
In this case, the force of mortality for individual i at instantaneous age x is
ui(x) = ziae
(bx)e
a ebx − 1
b ,
(6a)
Or
ln ui(x) = ln(a) + bx +
a ebx − 1
b + ln Zi .
(6b)
The rate of increase in mortality rate at age x is the derivative of ln(ui(x)) at age x, i.e., 
dln ui(x)
dx = b + ae
bx
 In other words, the rate of individual mortality acceleration itself is a 
Gompertz function of age x; it increases as age increases. By assuming individual hazard 
function as formula (6a) or (6b), the simulated cohort mortality curve will follow a 
Gompertz function ū(x) = aeβx. For a detailed description of simulation procedure, please 
refer to Appendix A and B.
In reality, the distribution of frailty may be more complicated than what was assumed in the 
main models (Wrigley-Field 2014). It is beyond the scope of this paper to conduct a 
comprehensive comparison of these various specifications, but it is helpful to explore some 
potential implications and point to possible directions for future work. Several auxiliary 
simulations are presented in this spirit. In Appendix C, we experiment with two sets of 
models, in which (1) the frailty distribution is allowed to vary by subgroups in the 
population, and (2) the severity of frailty is allowed to vary across the life cycle, both 
linearly and non-linearly. The results are overall consistent with our simplified model, and 
we note that further development of the model to incorporate variations across subgroups is 
needed in future research.
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Results
Micro mechanisms for cohort evolution
In order to examine the micro mechanisms for cohort evolution (Conjecture 1), we do one 
scenario of simulation as presented in Figure 3. We set variance of frailty distribution σ2 and 
parameter b fixed at three cohorts and only allow ln(α) decreases. The simulation result on 
the left panel supports the cohort evolution theories that cohorts with lower young-age 
mortality rates have lower mortality rates over the life course. The right panel portrays the 
mortality curves of the standard individual (frailty level zi = 1) among these three cohorts. 
The standard individuals among later cohorts with lower mortality rates at age 30 have 
smaller rates of mortality acceleration that cause them to have lower mortality rates over the 
life course. According to the formula for rate of mortality acceleration at the individual 
level, b + aebx, it is obvious that it is affected by initial mortality rate a, but not affected by 
the variance of frailty distribution σ2. This provides a micro explanation for the cohort 
evolution mechanism portrayed in the left panel. Overall these simulations support 
Conjecture 1.
Micro mechanisms for mortality selection
The left panel of Figure 3 also tests Conjecture 3. It finds that cohorts with lower young-age 
mortality rates do not have a steeper but paralleling slope of mortality acceleration β at the 
cohort level. This refutes Conjecture 3. In order to test Conjecture 2, we set ln(α) and b fixed 
at three cohorts and only allow variance of frailty distribution σ2 decreases as presented in 
Figure 4. The simulation result on the left panel supports the proposition from the theory of 
population heterogeneity that cohorts with a smaller variance of frailty at young age do have 
a steeper slope of mortality acceleration. Therefore, opposite to the forces driving the rate of 
mortality acceleration at the individual level, the rate of mortality acceleration at the cohort 
level β is affected by the variance of frailty distribution σ2, but not by initial mortality rate a. 
The right panel further portrays the micro forces driving the steeper slope among cohorts 
with smaller σ2 on the left panel: variance of frailty declines over the life course and it 
declines at a lower rate among cohorts with a smaller variance of frailty at initial age. Thus, 
a smaller proportion of frail individuals are selected out of the population at initial age, 
leaving a relatively larger proportion of frail individuals to survive to older ages and making 
the mortality curve steeper. These simulations suggest the negative correlation between ln(α) 
and β observed in Strehler and Mildvan (1960) is due to the negative correlation between σ2 
and β and the general positive correlation between ln(α) and σ2, meaning that the cohorts 
with lower initial mortality rates tend to have smaller variance of frailty.
Simulating Swedish male mortality pattern
In order to test Conjecture 4, we simulate the male mortality pattern in the cohorts of 1801, 
1851, and 1901 in Sweden. We set ln(α) at the levels of log mortality rates at age 30 among 
these three cohorts to facilitate cohort evolution mechanism, and let b equal 0.061. We let σ2 
decrease across these three cohorts to facilitate the mortality selection mechanism suggested 
1Following Vaupel and Yashin (1983), we set b fixed at certain values. We tried different values of b; 0.06 best approximates the 
observed mortality pattern.
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by conjecture 2. The left panel of Figure 5 portrays a cohort pattern from this simulation, 
which replicates the observed pattern. This supports Conjecture 4 that the Swedish cohort 
mortality pattern is a joint outcome of cohort evolution and mortality selection mechanisms.
Simulating Bulgarian male mortality pattern
In order to test Conjecture 5 and 6, we try to simulate the male mortality pattern in the 1930 
and 1940 cohorts in Bulgaria. Conjecture 5 implies that the variance of frailty distribution at 
early adulthood among later cohorts could have been the same or even larger than that of 
proceeding cohorts. So we simulate five scenarios where we set ln(α) at the levels of log 
mortality rates at age 30 among these two birth cohorts as shown in Figure 6. We let σ2 be 
constant (σ2 = 2) or increase (σ2 = 4, σ2 = 8) across these two cohorts. But contrary to the 
predictions in Conjecture 5, the simulated 1940 cohort either has a paralleling or flatter slope 
than the 1930 cohort. In any case, there is no mortality crossover. These three scenarios 
reject Conjecture 5.
In fact, if we only allow cohort forces in effect, we have to substantially decrease instead of 
increase the variance of frailty distribution among the 1940 cohort in order to create the first 
mortality crossover at age 40 as shown in scenarios (σ2 = 0.5, σ2 = 0.25). Because the 
variance of frailty is unobserved, there is no way to use empirical data to either support or 
dispute this decrease in variance within 10 years of birth cohorts. But compared to the 
decrease in variance within every 50 years of cohorts in the simulations for Sweden, we note 
that this amount of decrease to be unrealistic for Bulgaria. These simulations demonstrate 
that there is no way to produce the empirical cohort pattern in Bulgaria by only allowing 
cohort mechanisms in effect. The mortality crossover across birth cohorts must have been 
caused by period shocks.
Figure 7 shows the trends in age-specific mortality rates ages 20–74 across time periods 
from 1947 through 2010 in Bulgaria. Mortality rates within the age groups 30–59 increased 
from the mid-1960s until the mid-1990s, which caused later cohorts to have higher mortality 
rates than earlier cohorts at each age within this age range. Mortality rates before age 30 and 
after age 60, however, did not significantly increase from the mid-1960s through the 
mid-1990s. This may have generated the two-step crossover in mortality rates across 
cohorts.
Discussion and Conclusion
This study uses microsimulation method based on mathematical models to investigate the 
role of cohort forces (cohort evolution and mortality selection) in age-dependent mortality 
pattern. We show that cohort evolution is due to the declining rate of mortality acceleration 
at the individual level, which is associated with lower initial mortality rates but not smaller 
variance of frailty distribution in later birth cohorts. The steeper slope of mortality 
acceleration at the population level among later cohorts is due to the mortality selection 
mechanism associated with a smaller variance of frailty distribution but not lower initial 
mortality rates among later cohorts. Our simulations further imply that even though the 
prominent mechanisms for receding pandemics are different between early-and later-
transition countries, their cohort patterns in age-dependence of mortality rates still resemble 
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each other. That is because vaccination and medical technology can still trigger the 
emergence of cohort evolution mechanisms due to the gained nutrition status from the 
reduction of exposure, duration and severity of infection caused by them (Scrimshaw 1992; 
Palloni and Souza 2013). Frailty arguments rely on the long lasting negative consequence of 
poor nutrition and exposure to infection and inflammation in early life on adult health 
compared to those with good nutrition and no or less exposure to infection and 
inflammation. But the reference group for historical cohort comparison is earlier cohorts 
with similar or even worse nutrition and exposure to infection and inflammation. Compared 
to these earlier cohorts, later cohorts are still better off because lower contraction rate of 
infectious diseases (due to vaccination) and reduced duration and severity of infection and 
better recovery from diseases (due to medical treatment) can be translated to better nutrition 
status even in the absence of improvement in nutrition intake.
The mortality crossover in some later transition countries should not have been caused by 
the mortality selection mechanism, but instead should have been caused by period shocks. 
Particularly, in the context of Central and Eastern Europe, economic stagnation during cold 
war have contributed to the increasing middle-age (age 30–59) mortality rates (e.g., suicide 
rate) after the 1970s. Economic difficulties might also have held back the dissemination of 
expensive new technologies (Vallin and Meslé 2004). Moreover, health system failed to 
respond to the epidemiological transition of the population (Dimova et al. 2012). The highly 
centralized social system, which succeeded in fighting infectious diseases before the 1970s, 
worked to their disadvantage in getting individuals to take responsibility for their own health 
through behavioral and lifestyle changes (Vallin and Meslé 2004). Bulgaria had experienced 
a dramatic increase in the consumption of ethanol and animal fat, tobacco and alcohol since 
the early 1970s, that exacerbated the upward trend in mortality rates from cancer, stroke, 
cardiovascular disease (CVD) and non-CVD among people in early and middle adulthood, 
especially in men (Kubik et al. 1995; Georgieva 2002; Caselli et al. 2002). This has caused 
the two-step mortality crossover within this age group across successive birth cohorts. 
Mortality rates, especially the cardiovascular death rate, has declined sharply in Bulgaria 
since the mid-1990s (Meslé, 2002; Karanikolos et al. 2017), so mortality rates stop crossing 
over among the recent birth cohorts.
This study implies that observed or expected rising mortality in middle or late adulthood in 
the later period among later-transition countries might not be due to reduced mortality 
selection in early life in early periods. Studies have found that, in low- and middle-income 
countries, middle-aged adults are especially vulnerable to chronic diseases. Individuals in 
these countries tend to develop chronic diseases at younger ages, suffer from more 
complications, and die sooner than individuals in high-income countries (World Health 
Organization 2005; Vallin and Mesle 2004). Our simulation, however, implies that rising 
mortality conditions in middle and old age in later periods should not be caused by blunted 
mortality selection in early periods because medicine-induced infection alleviation can be 
translated into better nutrition status. Instead, period factors—including changes in air 
pollution, environmental degradation, economic stagnation, urbanization, nutrition 
transition, unhealthy diet, and a sedentary lifestyle—might have caused increased chronic 
disease burdens in later-transition countries (Caballero and Popkin 2002; Chen et al. 2013; 
Pimentel 2007; Smith 2000; Vallin and Mesle 2004; Yusuf 2001).
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Appendix A.: Simulation procedure
We start our simulation from age 30 because cohort mortality curve follows a Gompertz 
curve beginning around that age (Gompertz 1825). We let a in (6b) equal the observed 
cohort mortality rate at age 30, which represents the mean of mortality hazards across 
individuals within this cohort at initial age. So it equals the mortality hazard for a “standard” 
individual with frailty of 1.2
Our simulation proceeds in every one year of age among a hypothetical population of 
1,000,000 individuals. On the individual level, the force of mortality ui (x) should change 
continuously within each tiny age interval. But we assume it is constant within each one year 
of age, denoted as ui* (so-called piecewise-constant force of mortality assumption). 
Piecewise-constant force of mortality is a reasonable assumption for a small age interval like 
one year. It also has computational advantages: it can easily convert hazard rate to 
probability and save enormous computation time. Under this assumption, the central 
mortality rate with each year of age for every individual i, mx
i
 equals ui*. Then the probability 
of surviving between age x and x + 1 for every individual i, denoted as px
i
, equals e
−mx
i
(Preston et al. 2001). The simulation process proceeds from age to age. At each age, we 
calculate the probability of dying for each surviving individual at age x as qx
i = 1 − px
i
 and 
then perform a random draw following a binomial distribution where the probability of 
getting a value of 1 equals qx
i
. Individuals who receive a value of 1 will die between age x 
and x+1. We stop the simulation at age 90 for the Swedish population as mortality patterns 
past age 90 do not typically follow the Gompertz curve (Vaupel 1997). We stop the 
simulation at age 70 for the Bulgarian population to more closely examine the pattern within 
this age range.
After generating the simulated cohort survival data, we next calculate the cohort age- 
dependent mortality rate. An important step here is to calculate the person-years. We hold 
the same piecewise-constant force of mortality assumption like the one in the simulation 
procedure. Under this assumption, person-years within each one-year age interval equals. 
lx + 1 − lx
ln
lx + 1
lx
 is the number of people left alive at age x (Preston et al. 2001). The cohort age-
dependent mortality rates are calculated as the number of dead divided by this measure of 
person-years within each one-year age interval.
In different rounds of simulations, we alter the values of initial mortality rate (ln(a)) and the 
variance of frailty parameter (zi) (i.e., σ2) in specifying the individual-level mortality hazard 
to experiment with different cohort conditions. We then compare the resulting cohort 
mortality rate to decide what micro-level changes in mortality patterns are likely to occur in 
order to produce the observed cohort-level mortality patterns.
2We also experimented with holding the natural logarithm of z constant across cohorts instead of holding the value of z constant. 
Results show no substantial change with the alternative specification.
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Appendix B.: The relationship between individual and cohort mortality 
functions
Before testing the six conjectures, we test assumptions about the unobserved individual 
hazard function specified in formulas (6b). Some studies have assumed individual hazard 
curve as a Gompertz function in human populations (Service 2000; Wrigley-Field 2014). 
The model can be specified:
u0(x) = ae
bx, (7)
where a is the hazard at initial age and b is the rate of mortality acceleration. Replacing u0(x) 
in formula (1) with formula (7), we get the force of mortality for individual i at 
instantaneous age x
ui(x) = ziae
bx, (8a)
Or
ln ui(x) = ln(a) + bx + ln zi . (8b)
The rate of increase in mortality rate at age x is the derivative of ln(ui(x)) at age x, i.e., 
dln ui(x)
dx = b. In other words, individual log mortality curve is a linear function of x with 
fixed slope b. However, by assuming individual hazard function as formula (8a) or (8b), the 
simulated cohort mortality curve will “age” even slower than Gompertz, which does not 
accurately characterize the empirical cohort mortality pattern.
The left panel of Appendix Figure B1 portrays the simulated cohort mortality pattern from 
age 30 to 90 based on these two different hazard function assumptions (i.e., 6b and 8b). 
Cohort 1 is based on formula (6b) and cohort 2 is based on formula (8b); we set the same 
values of log mortality rate at age 30 (= −4.529) and variance of frailty distribution σ2 (=1) 
and b
(=0.06). Cohort 1 observes a linear slope of log mortality rate at cohort level, which is 
consistent with the empirical pattern (i.e., Gompertz mortality curve). In contrast, cohort 2 
observes a declining rate of mortality increase during this age range, which is inconsistent 
with the empirical pattern. In other words, Gompertz assumption of individual hazard 
function will generate a cohort which ages slower than Gompertz. The difference in these 
simulated cohort patterns is not contingent on different values of ln(α), σ2 and b. This leads 
to our decision to use formula (6b) as a basis for further simulation.
The right panel of Appendix Figure B1 further portrays the relationship between individual 
hazard curve (based on formula 6b) and the corresponding cohort mortality curve. For any 
given birth cohort, there are numerous individual hazard curves with different frailties zi but 
the same shape of mortality acceleration (b + aeb x). We present the curve for the “standard” 
individual with frailty level zi = 1, which puts the initial mortality rate at age 30 in line with 
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cohort mortality rate at age 30 and makes the comparison more straightforward. As 
demonstrated in this figure, cohort log mortality curve follows a linear function. More 
importantly, cohort mortality rate increases at a slower rate than the individual mortality rate, 
which is due to the mortality selection mechanism that removes frailest individuals at earlier 
ages and causes the cohort mortality pattern to be increasingly dominated by robust 
individuals over the life course.
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Appendix Figure B1. 
Simulated cohort age-dependence of mortality pattern based on different assumptions of 
unobserved individual hazard function
Appendix C.: Auxiliary Simulations Demonstrating Mortality Patterns under 
More Complex Assumptions about Frailty Distribution in the Population.
In our main simulations, we have assumed that the frailty for each cohort is distributed as a 
Gamma distribution. In keeping with the main aim of our paper, which is to examine the 
impact of the mortality selection mechanism on changes in cohort mortality patterns, we 
have focused on the changes in the variance of the frailty distribution across cohorts. 
However, as Wrigley-Field (2014) suggested, in reality, the distribution of frailty may be 
more complicated than what was assumed in the main models. It is beyond the scope of this 
paper to conduct a comprehensive comparison of these various (and arguably more realistic) 
specifications, but we think it is helpful to explore some of the potential implications and 
point to possible directions for future work. The following auxiliary simulations are 
presented in this spirit. Here, we experiment with two sets of models, in which (1) the frailty 
distribution is allowed to vary by subgroups in the population, and (2) the severity of frailty 
is allowed to vary across the life cycle, both linearly and non-linearly.
Auxiliary Simulations 1: Different Frailty Distributions across Subgroups of 
the Population
In the first set of auxiliary simulations, we explore the potential subgroup variations in the 
distribution of frailty. To do this, in Appendix Figure C1, we compare the simulation results 
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based on our original specification in the main analysis with those based on the assumption 
that the population is composed of two subgroups, with the percentage of the majority group 
being 90% (the left plot) and 70% (the right plot), respectively. In each plot, we further 
explored three possible frailty distributions of the added subgroup: (1) adding a subgroup 
with a higher frailty variance than the majority group; (2) adding a subgroup with a higher 
baseline mortality rate; (3) adding a subgroup with both a higher frailty variance and higher 
baseline mortality rate.
Appendix Figure C1 presents these results. Consistent with our main results, adding a higher 
variance group leads to a flatter cohort mortality curve over age (e.g. the red dashed line is 
flatter than the black solid line in the original specification). As can be expected, the 
addition of a subgroup with higher baseline mortality rate will shift the mortality curve 
upwards, because the “average individual” in this cohort becomes frailer. In addition, the 
larger the minority subgroup (30% versus 10%), the more pronounced the difference is 
between the new and original specifications. One interesting observation from these results 
is that, the effect of adding a high variance subgroup is stronger when the added subgroup’s 
baseline mortality rate is the same as the majority subgroup, and becomes much milder 
when the added subgroup’s baseline mortality rate is relatively higher (e.g. the difference 
between the green and blue lines is smaller than that between the red and black lines). This 
suggest that, when the population is composed of multiple subgroups, the impact of frailty 
variance and mortality selection may also depend on the baseline frailty of these subgroups, 
a direction worth exploring in future research. But overall, the inverse relationship between 
variance of frailty and slope of mortality acceleration at the population level are supported in 
these simulations.
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Appendix Figure C1. 
Simulation Results with Two Frailty Groups
Auxiliary Simulations 2: Age-varying Severity of Frailty
In the second set of auxiliary simulations, we explore the implications of allowing the 
severity of frailty to vary linearly and non-linearly with age. This may be a reasonable 
assumption, because the risks of frailty may evolve in complex ways not just across 
subgroups, but also within a cohorts’ life cycle. We present the results from our auxiliary 
simulations in Appendix Figure C2. In the left plot, we allow frailty to increase linearly with 
age, and compare the resulting cohort mortality curves under relatively low and high rates of 
the linear increase with the curve from our original specification, which assumes a constant 
severity of frailty over the life cycle. As the results demonstrate, increasing severity of frailty 
increases the steepness of the cohort mortality curve, implying that this increase will lead to 
a faster mortality process. In addition, the plot also shows that this effect is stronger before 
age 60, and becomes milder at older ages. In other words, the results suggest that the 
increasing severity of frailty on the individual level affects the mortality rate on the cohort 
level the most during middle life.
The linear increase in the severity of frailty may be unrealistic, in that the age-varying 
severity of frailty may reach its peak at a certain point in the life course, and the severity of 
frailty for different cohorts/individuals may also peak at different ages. We therefore include 
an additional round of simulations, in which we specify the individual-level severity of 
frailty as a quadratic function of age, with the coefficient on the squared term of age being 
negative. This non-linear specification allows the severity of frailty to increase at a faster rate 
during younger ages, but the increase will slow down at older ages. The right plot of 
Appendix Figure C2 shows the results from two such simulations, one with a relatively 
earlier peaking (red dashed line) and the other with later peaking (blue dash-dotted line). As 
may be expected, the cohort mortality curve in the earlier-peaking case goes up faster than 
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that in the later-peaking case, because the severity of frailty took off at a faster rate in the 
former. Yet, at around age 70, the two curves cross over each other, with the mortality curve 
for the later-peaking case taking a higher position. This is driven by the fact that severity of 
frailty in the earlier-peaking case has slowed down at later ages, while the frailty in the later-
peaking case kept climbing after this age.
In this study, we focus on the demographic frailty and the variance of frailty as the key factor 
affecting cohort mortality patterns, rather than biological frailty. Although demographic 
frailty is fixed at birth, since individual mortality risk is a product between its demographic 
frailty as well as standard individual (frailty of 1) mortality risk, our simple model does 
imply biological frailty varies over life course. Our model also produces the linear mortality 
curve at cohort level at the log scale, consistent with empirical pattern. As these auxiliary 
simulations demonstrate, it may not be straightforward to replicate the observed linear log 
mortality curve at the population level under the assumption of age-varying severity of 
frailty, and thus additional assumptions or alternative specifications may be introduced to 
better replicate the empirical pattern. While future work can more carefully explore the more 
complex, dynamic patterns of individual biological frailty, it should be mindful about the 
implication of these patterns on the empirical cohort mortality pattern.
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Appendix Figure C2. 
Simulation Results with Linear and Non-linear Age-varying Severity of Frailty
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Figure 1. 
An illustration of log Gompertz mortality curve across two hypothetical cohorts
Note: ln(ū (x)) represents the logarithm transformation of age-specific mortality rate at age 
x.
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Figure 2. 
Cohort changes in age-specific mortality rates over the life course in various countries
Note: Data for Sweden, Japan, Bulgaria and Taiwan are from the Human Mortality Database 
(HMD). Data for Mexico and Chile are from Latin American Mortality Database 
(LAMBdA). Cohort age-specific mortality rates for Mexico and Chile are constructed from 
the period data provided by LAMBdA so they may not be completely accurate. ln(ū(x)) 
represents the logarithm transformation of age-specific mortality rate at age x.
Zheng and Cheng Page 23
Biodemography Soc Biol. Author manuscript; available in PMC 2019 December 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. 
Testing micro mechanisms for cohort evolution
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Figure 4. 
Testing micro mechanisms for mortality selection
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Figure 5. 
Simulate Swedish male mortality pattern with cohort evolution and mortality selection 
mechanisms
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Figure 6. 
Simulate Bulgarian male mortality patterns
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Figure 7. 
Period changes in age-specific mortality rates ages 20–74 in Bulgaria, 1947–2010
Note: Data are from the Human Mortality Database. ln(ū (x)) represents the logarithm 
transformation of age-specific mortality rate at age
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